Evaluation of clinical data and features of immunopathogenesis, along with molecular genotyping, open up new possibilities for a personalized approach to the prevention and treatment of occupational bronchial asthma. The aim is to determine clinical, immunological and genetic markers of the risk of developing occupational bronchial asthma under exposure to sensitizing substances based on the results of an assessment of polymorphic variants rs2069812 of the IL5 gene. The study included 170 patients with various phenotypes of occupational bronchial asthma and 50 people in the control group. The levels of MCP-1 cytokines and total IgE in blood serum were determined by solid-phase enzyme immunoassay using standard reagent kits. The serum content of vascular endothelial growth factor (VEGF) was studied by sandwich-type solid-phase enzyme immunoassay. Genotyping was performed by polymerase chain reaction. During the study, the features of clinical and immunological manifestations depending on the phenotype of occupational bronchial asthma were established for the first time, genetic markers of the risk of developing this pathology under the influence of sensitizing substances were identified: polymorphic variants rs2069812 of the IL-5 gene.
Read full abstract